autoclaved leishmania antigen

Autoclaved Leishmania antigen (ALA) is a first-generation, whole-organism inactivated vaccine candidate designed for the prevention and treatment of various forms of leishmaniasis, particularly cutaneous leishmaniasis. The vaccine is prepared by harvesting promastigotes of Leishmania species, such as *L. major* or *L. amazonensis*, which are then washed and subjected to autoclaving to render the parasites non-viable while maintaining the integrity of key immunogenic proteins. ALA functions by stimulating a cell-mediated immune response, specifically promoting a Th1-type cytokine profile characterized by the production of interferon-gamma (IFN-γ) and interleukin-12 (IL-12). This immune shift is critical for activating macrophages to eliminate intracellular Leishmania parasites. ALA has been extensively studied in Phase 2 and Phase 3 clinical trials in endemic regions like Iran, Sudan, and Brazil, often administered alongside the BCG (Bacille Calmette-Guérin) vaccine, which serves as a potent adjuvant to enhance the Th1 response.

Other names

Autoclaved Leishmania major antigenAutoclaved Leishmania amazonensis antigenKilled Leishmania vaccine